Craft

Kannalife

Stock Price

$0.2

2021-01-28

Market Capitalization

$25.2 M

2021-01-28

Revenue

$183.5 K

FY, 2021

Kannalife Summary

Company Summary

Overview
Kannalife is a biopharmaceutical company focused on the research and development of cannabinoid therapeutics. It provides proprietary cannabidiol (CBD) and CBD-like molecules for patients suffering from neurodegenerative disorders, including chemotherapy-induced peripheral neuropathy (CIPN), hepatic encephalopathy (HE), mild traumatic brain injury (mTBI), and chronic traumatic encephalopathy (CTE).
Type
Public
Status
Active
Founded
2010
HQ
Doylestown, PA, US | view all locations
Website
https://www.kannalife.com/
Cybersecurity rating
Sectors

Key People

  • Dean Petkanas

    Dean Petkanas, Chairman & CEO

    • William A. Kinney

      William A. Kinney, Chief Scientific Officer

      • Mark Corrao

        Mark Corrao, Chief Financial Officer

        • Thoma Kikis

          Thoma Kikis, Founder / Chief Communications Officer, Board Director

          LocationsView all

          1 location detected

          • Doylestown, PA HQ

            United States

            3805 Old Easton Rd

          Kannalife Financials

          Summary Financials

          Revenue (Q1, 2022)
          $208.0K
          Net income (Q1, 2022)
          ($1.6M)
          Cash (Q1, 2022)
          $102.2K
          EBIT (Q1, 2022)
          ($366.4K)

          Footer menu